Claims for Patent: 7,374,914

Summary for Patent: 7,374,914

Title:	Method of detection of alterations in MSH5
Abstract:	We have now discovered that mammals have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human, can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer: We have discovered and sequenced MSH5 in a number of mammals, including humans. This gene can be used in assays, to express gene product, for drug screens, and therapeutically.
Inventor(s):	Kolodner; Richard (San Diego, CA), Winand; Nena (Freeville, NY)
Assignee:	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:	10/680,386
Patent Claims:	1. A method of determining an alteration in a nucleic acid encoding human MSH5 gene, wherein said human MSH5 is encoded by SEQ ID No.: 1, the method comprising analyzing a nucleic acid in a biological sample for an alteration in the SEQ ID No.: 1 by comparing the nucleic acid in the biological sample to that of the sequence of SEQ ID NO: 1 wherein a difference in the nucleic acid in the sample compared to SEQ ID NO: 1 represents an alteration in human MSH5 gene. 2. The method of claim 1, wherein the biological sample is selected from blood, tissue, serum, stool, urine, sputum, cerebrospinal fluid, supernatant from cell lysate and a eukaryotic cell sample. 3. The method of claim 1, wherein the analyzing is performed using mRNA in the biological sample. 4. The method of claim 1, wherein the analyzing is performed using DNA in the biological sample. 5. The method of claim 1, wherein the biological sample is from an individual affected with cancer. 6. The method of claim 1, wherein the biological sample is from an individual affected with infertility. 7. The method of claim 1, wherein the alteration is detected using a pair of oligonucleotide primers that hybridize to SEQ ID NOs: 3-26 or 27-50. 8. The method of claim 1, wherein the analysis is performed using nucleic acid sequencing. 9. The method of claim 1, wherein the comparison is made by looking at a genomic sample by looking at at least one individual exon. 10. The method of claim 1, wherein the alteration is determined using restriction fragment length polymorphism using a probe or probes that specifically bind to SEQ ID NO: 1. 11. The method of claim 1, wherein the alteration is a deletion within SEQ ID NO: 1. 12. The method of claim 1, wherein the alteration is a point mutation within SEQ ID NO: 1. 13. A method of determining an alteration in a nucleic acid encoding human MSH5 comprising the steps of (a) amplifying a nucleic acid from a biological sample with primers that specifically hybridize to SEQ ID NO:1; and (b) comparing the amplified nucleic acid to SEQ ID NO: 1, wherein a difference in the nucleic acid from the biological sample compared to the corresponding sequence region in SEQ ID NO: 1 is indicative of an alteration in the nucleic acid encoding human MSH5. 14. The method of claim 13, wherein at least one pair of the primers specifically hybridize to one of the exon/intron borders of human MSH5. 15. The method of claim 14, wherein the human MSH5 exon/intron borders are selected from SEQ ID NOs: 3-26 and 27-50. 16. The method of claim 1, wherein the comparison is made by looking at a coding region of the SEQ ID NO: 1. 17. The method of claim 1, wherein the comparison is made by looking at a non-coding region of the SEQ ID NO: 1.

Details for Patent 7,374,914

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-03